Doggrell S.A. .2018 .Semaglutide in Type 2 Diabetes - Is It the Best Glucagon-Like Peptide 1 Receptor Agonist (GLP-1R Agonist)?” Expert Opinion on Drug Metabolism ansd Toxicology. , 1441286(2018) : 371-377.
Goldenberg R.M.,Steen O. .2018 .Review and Place in Therapy for Adults with Type 2 Diabetes. Canadian Journal of Diabetes, 05(2019) : 136-145.
.2022 .. , : .
Bradley C.L. . .Tirzepatide, the newest medication for type 2 diabetes: A review of the literature and implications for clinical practice. The Annals of Pharmacotherapy, 57(2023) : 822-836.
Dougherty T.,Heile M. .2020 .Type 2 diabetes in the US managed care setting: The burden of disease and rationale for an oral glucagon-like peptide-1 receptor agonist. The American Journal of Managed Care, 88552(16 Suppl.) : S325-S334.
Singh G. .001952 .Wegovy (Semaglutide): A new weight loss drug for chronic weight management. ” Journal of Investigative Medicine, 70(2022) : 5-13.
Phillips A.,Clements J.N. . .Clinical review of subcutaneous semaglutide for obesity. ” Journal of Clinical Pharmacy and Therapeutics, 47(2022) : 184-193.
Amaro A. .2022 .Efficacy and safety of semaglutide for weight management: evidence from the STEP program. Postgraduate Medicine, 2147326(2022) : 5-17.
Capla J,Hanna S.A. .2023 .Patient evaluation and surgical staging. ” Clinics in Plastic Surgery, 07(2024) : 7-12.
Liebisch-Rey H. .2023 .The short-term cost-effectiveness of once-weekly semaglutide versus once-weekly dulaglutide for the treatment of type 2 diabetes mellitus in colombian adults. ” F1000Research, 12 : 914.
Chen J. .2022 .GLP-1 receptor agonist as a modulator of innate immunity. , 997578 : 997578.
Millar B.,M. de Gaetano B. .2023 .“Posing the rationale for synthetic Lipoxin mimetics as an adjuvant treatment to gold standard atherosclerosis therapies. , 1125858 : 1125858.
Andersen D.B. and J.J.,Holst D.B. and J.J. .2021 .Peptides in the regulation of glucagon secretion. ” Peptides, 170683 : 170683.
Queiroz V. N. F. .2023 .Risk of pulmonary aspiration during semaglutide use and anesthesia in a fasting patient: A case report with tomographic evidence. Einstein (São Paulo), 21 : .
Tsamos G. .2023 .Therapeutic potentials of reducing liver fat in non-alcoholic fatty liver disease: Close association with type 2 diabetes. ” Metabolites, 13 : 517.
Sodhi M. .2023 .Risk of gastrointestinal adverse events associated with glucagon-like peptide-1 receptor agonists for weight loss. ” JAMA, 19574(18) : 1795-1797.
Lenharo M. .2023 .Anti-Obesity drugs' side effects: What we know so far. ” Nature, 622(7984) : 682.
Silbert R. . .Hypoglycemia among patients with type 2 diabetes: Epidemiology, risk factors and prevention strategies. ” Current Diabetes Reports, 18(2018) : 53.
Aroda V.R. . .Safety and tolerability of semaglutide across the SUSTAIN and PIONEER Phase IIIa clinical trial programmes. ” Diabetes, Obesity & Metabolism, 25(2023) : 1385-1397.
Nevola R. . .GLP-1 receptor agonists in non-alcoholic fatty liver disease: Current evidence and future perspectives. International Journal of Molecular Sciences, 24(2023) : 1703.
Flint A. . .Randomised clinical trial: Semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging. ” Alimentary Pharmacology and Therapeutics, 54(2021) : 1150-1161.
Bandyopadhyay S. .2023 .Role of semaglutide in the treatment of nonalcoholic fatty liver disease or non-alcoholic steatohepatitis: A systematic review and meta-analysis. ” Diabetes and Metabolic Syndrome, 102849(10) : 102849.
Suvarna S. K.,Elsevier S. K. .2019 .. Bancroft's Theory and Practice of Histological Techniques. 8th Edn, : .
Jo T. .2021 .Risk of drug-induced interstitial lung disease in hospitalised patients: A nested case-control study. ” Thorax, 76(12) : 1193-1199.
Rossi S.E. . .Pulmonary drug toxicity: Radiologic and pathologic manifestations. ” Radiographics, 20(2000) : 1245-1259.
Zoccali C. .2013 .Lung congestion as a risk factor in end-stage renal disease. ” Blood Purification, 36 : 184-191.
Ceridon M. .2009 .Does the bronchial circulation contribute to congestion in heart failure?” Medical Hypotheses. , 03(2009) : 414-419.
Ahmed S.T. . .The histological effects of methotrexate on the lungs of albino rats: An experimental study. European Journal of Molecular and Clinical Medicine, 8(2021) : 1289-1297.
Drent M. . .Drug-induced pneumonitis and heart failure simultaneously associated with venlafaxine. American Journal of Respiratory and Critical Care Medicine, 167(2003) : 958-961.
Sunaga H. .2013 .Deranged fatty acid composition causes pulmonary fibrosis in Elovl6-deficient mice. Nature Communications, 4 : .
Wynn T.A. . .Pulmonary fibrosis: Pathogenesis, etiology and regulation. ” Mucosal Immunology, 2(2009) : 103-121.
Petta A.D. . .Histopathological characteristics of pulmonary emphysema in experimental model. ” Einstein, 12(2014) : 382-383.
Sarhan O.M. .2020 .Impact effect of methyl tertiary-butyl ether: Twelve months vapor inhalation study in rats. ” Biology, 9(2) : .
Parekh D. . .Acute lung injury. Clinical Medicine, 11(2011) : 615-618.
Assaad S. . .Assessment of pulmonary edema: Principles and practice. ” Journal of Cardiothoracic and Vascular Anesthesia, 32(2017) : 901-914.
.2016 .. , : .